Redeye comments on Alzinova’s recent announcements of a strategic collaboration with Worldwide Clinical Trials and promising new CSF data. We see the selection of Worldwide as CRO for the upcoming phase II trial as a positive step, given its strong track record in managing large-scale Alzheimer’s studies. In addition, we are also encouraged by the new CSF findings supporting ALZ-101’s ability to elicit an immune response that reaches the brain.
LÄS MER
